Glecaprevir (formerly ABT-493) is a novel hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) with pangenotypic activity. It inhibited the enzymatic activity of purified NS3/4A proteases from HCV genotypes 1 to 6 in vitro (half-maximal [50%] inhibitory concentration = 3.5 to 11.3 nM) and the replication of stable HCV subgenomic replicons containing proteases from genotypes 1 to 6 (50% effective concentration [EC50] = 0.21 to 4.6 nM). Glecaprevir had a median EC50 of 0.30 nM (range, 0.05 to 3.8 nM) for HCV replicons containing proteases from 40 samples from patients infected with HCV genotypes 1 to 5. Importantly, glecaprevir was active against the protease from genotype 3, the most-difficult-to-treat HCV genotype, in both enzymatic and replicon assays demonstrating comparable activity against the other HCV genotypes. In drug-resistant colony selection studies, glecaprevir generally selected substitutions at NS3 amino acid position A156 in replicons containing proteases from genotypes 1a, 1b, 2a, 2b, 3a, and 4a and substitutions at position D/Q168 in replicons containing proteases from genotypes 3a, 5a, and 6a. Although the substitutions A156T and A156V in NS3 of genotype 1 reduced susceptibility to glecaprevir, replicons with these substitutions demonstrated a low replication efficiency in vitro. Glecaprevir is active against HCV with most of the common NS3 amino acid substitutions that are associated with reduced susceptibility to other currently approved HCV PIs, including those at positions 155 and 168. Combination of glecaprevir with HCV inhibitors with other mechanisms of action resulted in additive or synergistic antiviral activity. In summary, glecaprevir is a next-generation HCV PI with potent pangenotypic activity and a high barrier to the development of resistance.
The E2 protein is required for the replication of human papillomaviruses (HPVs), which are responsible for anogenital warts and cervical carcinomas. Using an NMR-based screen, we tested compounds for binding to the DNA-binding domain of the HPV-E2 protein. Three classes of compounds were identified which bound to two distinct sites on the protein. Biphenyl and biphenyl ether compounds containing a carboxylic acid bind to a site near the DNA recognition helix and inhibit the binding of E2 to DNA. Benzophenone-containing compounds which lack a carboxylic acid group bind to the beta-barrel formed by the dimer interface and exhibit negligible effects on the binding of E2 to DNA. Structure-activity relationships from the biphenyl and biphenyl ether compounds were combined to produce a compound [5-(3'-(3",5"-dichlorophenoxy)-phenyl)-2,4-pentadienoic acid] with an IC50 value of approximately 10 microM. This compound represents a useful lead for the development of antiviral agents that interfere with HPV replication and further illustrates the usefulness of the SAR by NMR method in the drug discovery process.
bThe development of direct-acting antiviral agents is a promising therapeutic advance in the treatment of hepatitis C virus (HCV) infection. However, rapid emergence of drug resistance can limit efficacy and lead to cross-resistance among members of the same drug class. ABT-450 is an efficacious inhibitor of HCV NS3/4A protease, with 50% effective concentration values of 1.0, 0.21, 5.3, 19, 0.09, and 0.69 nM against stable HCV replicons with NS3 protease from genotypes 1a, 1b, 2a, 3a, 4a, and 6a, respectively. In vitro, the most common amino acid variants selected by ABT-450 in genotype 1 were located in NS3 at positions 155, 156, and 168, with the D168Y variant conferring the highest level of resistance to ABT-450 in both genotype 1a and 1b replicons (219-and 337-fold, respectively). In a 3-day monotherapy study with HCV genotype 1-infected patients, ABT-450 was coadministered with ritonavir, a cytochrome P450 3A4 inhibitor shown previously to markedly increase peak, trough, and overall drug exposures of ABT-450. A mean maximum HCV RNA decline of 4.02 log 10 was observed at the end of the 3-day dosing period across all doses. The most common variants selected in these patients were R155K and D168V in genotype 1a and D168V in genotype 1b. However, selection of resistant variants was significantly reduced at the highest ABT-450 dose compared to lower doses. These findings were informative for the subsequent evaluation of ABT-450 in combination with additional drug classes in clinical trials in HCV-infected patients. (Study M11-602 is registered at ClinicalTrials.gov under registration no. NCT01074008.) H epatitis C virus (HCV) infection is a global health problem, with 160 to 180 million individuals infected worldwide (1, 2). Chronic HCV infection can lead to serious liver disease, including cirrhosis, liver failure, and hepatocellular carcinoma. There are 7 major HCV genotypes, which differ in their geographic distribution, disease progression, and response to therapy (3). In the United States, Europe, and Japan, genotype 1 is the most prevalent genotype, and globally it accounts for approximately 60% of HCV infections (4).Therapy for those infected with HCV genotype 1 improved with the approval of the NS3/4A protease inhibitors (PIs) telaprevir, boceprevir, and, more recently, simeprevir (5-10). Although the addition of a PI to pegylated interferon (pegIFN) and ribavirin (RBV) therapy significantly improved sustained virologic response (SVR) rates compared to those with pegIFN/RBV therapy alone, IFN-based therapies are associated with treatment-limiting toxicities (11). In addition, there are many patients who are ineligible for IFN-based treatment due to comorbidities such as depression (12). Early clinical trials with these PIs also demonstrated that drug resistance developed within days after initiation of treatment (13-15). The rapid selection of resistant variants is facilitated by a high rate of virus production and the infidelity of the HCV RNA polymerase (16). Thus, there is a need for effective treatme...
Epstein-Barr nuclear antigen 1 (EBNA-1) is the only viral protein required to support replication of Epstein-Barr virus during the latent phase of its life cycle. The DNA segment required for latent replication, oriP, contains two essential binding regions for EBNA-1, termed FR and DS, that are separated by 1 kilobase pair. The FR site appears to function as a replicational enhancer providing for the start of replication at the DS site. We have used electron microscopy to visualize the interaction of EBNA-1 with its binding sites and to study the mechanism for communication between the FR and DS sites. We have found that DNA-bound EBNA-1 forms a DNA loop between the FR and DS sites. From these results, we suggest that EBNA-1 bound to the replicational enhancer acts by a DNA-looping mechanism to facilitate the initiation of DNA replication. Occupancy of the DS site alone is highly sensitive to competition with nonspecific DNA. In contrast, occupancy of the DS site by looping from FR is largely resistant to the competitor DNA. These experiments support the concept that enhancers act in cis from nearby sites to provide a high local concentration of regulatory proteins at their target sites and to stabilize regulatory interactions. transcriptional regulation, recent work has demonstrated association ofDNA-bound proteins between sites involved in enhancer function by the bacterial NtrC protein (15), the mammalian Spl protein (16,17), the viral bovine papilloma E2 protein (18), and the Spl and E2 proteins (19). Our work on EBNA-1 has been directed toward two questions: Does replicational enhancement involve the protein-protein association ofDNA-bound EBNA-1? Why do enhancers typically act only from relatively close sites on the same DNA molecule?In the work reported here, we have used electron microscopy to study the interaction of EBNA-1 with its specific binding sites and to examine the ability of DNA-bound EBNA-1 to carry out protein-protein interactions. Our results demonstrate that EBNA-1 bound at the FR and DS sites associates to loop the intervening DNA. As reported in the accompanying paper, Frappier and O'Donnell (20) have also used electron microscopy to show this looping interaction. Based on the sensitivity of the EBNA-1 interaction at the DS site to competition with nonspecific DNA, we suggest that EBNA-1 acts in cis from the FR enhancer to stabilize the interaction of the protein at the DS site. Epstein-Barr virus (EBV) can establish a latent state in which the EBV genome is maintained as a circular plasmid (1, 2). Studies with plasmids derived from EBV DNA have established the functional requirements for replication during the latent state. The Epstein-Barr nuclear antigen 1 (EBNA-1) is the only viral protein required for replication from the EBV latent origin of replication, oriP (3, 4). The oriP region is composed of two essential segments separated by about 1 kilobase pair (kbp): (i) a family of repeats (FR) with 20 tandem copies of a 30-bp sequence and (ii) a dyad symmetry region (DS) with 4...
Epstein-Barr virus nuclear antigen 1 (EBNA1) can bind specifically to two clusters of sites within the Epstein-Barr virus plasmid origin of DNA replication (oriP). EBNA1 activates DNA replication mediated by oriP and can also activate transcription and retain DNA in cells when bound site specifically. EBNA1 bound to oriP physically links the two clusters of EBNA1-binding sites, resulting in loop formation by the intervening DNA. To elucidate the contribution of DNA linking by EBNA1 to its biological activities, we identified regions within it that can independently link DNAs to which they are bound. An electrophoretic mobility shift assay was used to detect this activity. Proteins which link DNA aggregate that DNA into large lattices. Proteins which cannot link DNA but still bind to DNA retard the mobility of that DNA but do not cause it to form lattices. Amino-terminal truncations were used to map the amino-terminal limit of a minimal DNA-linking domain approximately to amino acid 372 of EBNA1. To map the carboxy-terminal limit of this minimal domain, fusion proteins containing the DNA-binding domain of GAL4 and fragments of EBNA1 were generated and studied. This approach identified the carboxy-terminal limit of this minimal domain to be approximately amino acid 391 and verified its amino-terminal limit. Internal deletions within a truncated EBNA1 derivative verified the importance of this region. Two additional fragments of EBNA1, each of which independently conferred DNA-linking activity on the domain of GAL4 which binds DNA, were identified within amino acids 54 to 89 and amino acids 331 to 361. Therefore, EBNA1 contains at least three regions that can act independently to link DNAs and that may act in concert within intact EBNA1.
The plasmid origin of DNA replication of Epstein-Barr virus, oriP, is replicated once per cell division, employing cellular replication machinery and only one viral protein. To understand how replication from this origin is initiated and regulated, we purified this viral protein, EBNA1. EBNA1 was expressed in CV-lp cells by using an infectious simian virus 40 vector containing the EBNA1 gene. It was purified in two chromatographic steps to apparent homogeneity. The purified protein is capable of supporting transcription of the luciferase gene from a reporter plasmid carrying the FR enhancer element to which EBNA1 binds. EBNAl does not have oriP-dependent ATPase activity, indicating that it does not carry out an energy-dependent step in the initiation of DNA replication. However, EBNAl does mediate an association between the two elements of oriP. We measured this association by binding one of the elements, the enhancer element, to a solid matrix and measuring retention by this element of the other one, the initiator element, in the presence of EBNAl. This retention is specific for DNA fragments containing EBNAl-binding sites. EBNA1 thus can link the two elements of the origin, providing a locally high concentration of EBNA1 at the site of initiation of DNA replication. We propose that this association is important either (i) to affect DNA structure to allow a cellular helicase to initiate DNA strand separation or (ii) to bind replication proteins to bring them to the origin of replication.
The capacity to bind the Epstein-Barr viral protein EBNA1 increases the retention of the plasmid in dividing cells. This retention requires binding of multiple EBNA1 molecules for function, although significant retention activity is seen with fewer EBNA1 binding sites than are required to activate replication or transcription. The regions of EBNA1 that are required for increased plasmid retention overlap with those required for activation of transcription and replication. The similarities in traits of EBNA1 that are required for support of DNA replication and retention of plasmid DNA indicate that both may be mediated by interactions with an overlapping set of cellular proteins. A characteristic of latency for Epstein-Barr virus (EBV) is that the virus must be able both to replicate its DNA and to pass that DNA on to daughter cells. The latent replication system of EBV uses a simple, well-defined origin of replication,
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.